Emergent BioSolutions (EBS) Receivables - Net (2010 - 2026)

Emergent BioSolutions has reported Receivables - Net for 17 years, with the latest figure at $190.0 million in Q2 2026.

• On a quarterly basis, Receivables - Net rose 138.1% year-over-year to $190.0 million in Q2 2026; TTM through Jun 2026 was $190.0 million, a 138.1% increase from a year earlier, with the FY2025 full-year figure at $84.2 million, down 45.5% from the prior year.
• Receivables - Net was $190.0 million for Q2 2026 at Emergent BioSolutions, up from $121.6 million in the prior quarter.
• The five-year high for Receivables - Net was $290.1 million in Q2 2023, with the low at $79.8 million in Q2 2025.
• Average Receivables - Net over 5 years is $171.8 million, with a median of $178.4 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Receivables - Net sank 59.35% in 2025, then soared 138.1% in 2026.
• Over 5 years, Receivables - Net stood at $159.2 million in 2022, then increased by 19.97% to $191.0 million in 2023, then declined by 19.11% to $154.5 million in 2024, then sank by 45.5% to $84.2 million in 2025, then surged by 125.65% to $190.0 million in 2026.
• The last three Receivables - Net figures came in at $190.0 million (Q2 2026), $121.6 million (Q1 2026), and $84.2 million (Q4 2025), per Business Quant data.